| Open Document File Size: 17,83 KBShare Result on Facebook
City DUBLIN / / Company Eisai Inc. / Astex Pharmaceuticals Inc. / Janssen-Cilag International NV / Cilag GmbH International / Astex Pharmaceuticals Astex Pharmaceuticals / / Continent Europe / / Country United States / / / Event FDA Phase / / Facility College Hill Melanie Toyne-Sewell / FDA White Oak Campus / / IndustryTerm pharmaceutical / treatment of elderly acute myelogenous leukemia / / MedicalCondition AML Acute myeloid leukemia / uncontrolled infection / cancer / petechiae / chronic myelomonocytic leukemia / disease / leukopenia / myelodysplastic syndromes / hyperglycemia / refractory anemia / neutropenia / nausea / thrombocytopenia / fever / hepatic dysfunction / fatigue / diarrhea / infection / cough / tiredness / constipation / infections / elderly acute myelogenous leukemia / anemia / / Organization Food and Drug Administration / Oncologic Drugs Advisory Committee / / Person Rebecca Skye Dietrich / Timothy L. Enns / Susanna Chau / / / Position Manager Investor Relations susanna.chau@astx.com / Director aroemer@troutgroup.com / Managing Director / General / Senior Vice President Corporate Communications & Marketing tim.enns@astx.com Susanna Chau / Senior Vice President Corporate Communications & Marketing tim.enns@astx.com / / Product Dacogen / / ProvinceOrState California / / URL www.eisai.com / http /
SocialTag |
Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the